MyBioSource.com's Situin 1 antibody is a Rabbit Polyclonal antibody. This antibody has been shown to work in applications such as: Immunoprecipitation, and Western Blot. The Situin 1 antibody was generated using sir2, Sir2a, SIRT1, and sirtuin 1 as the antigen and it reacts with Mouse.
Description
Silent information regulators (Sir proteins) or atypical class III HDACs (NAD-dependent deacetylase proteins) is a member of the Sir2 family of NAD+- dependent protein deacetylases involved in caloric restriction-dependent life span extension in diverse organisms but their role in humans have not been elucidated fully. The cell survival is partly controlled by activity of NFkB and Sir 1 controls the transcriptional activity of NFkB. Sir1 is a mammalian homolog of yeast SIR2 (silencing Information Regulator) and is a member of a larger family of Sirtuin proteins (Sir1 thru Sir7) which are implicated in modulating transacriptional silencing and cell survival. Sir 1 interacts with RelA/p65 subunit of NF-kB and inhibits transcription by de-acetylating RelA/p65 at lysine 310 (1). SIRT1 plays an active role in inhibiting transcription by interacting with the basic helix-loop-helix proteins HES1, HEY2, and with the COUP-TF interacting protein 2 (CTIP2, 2). Sir1 also deactylates non-histone protein substrate, including TAFI68, PCAF, p300, MyoD, p53, and Ku 70. SIRT1 regulates cell fate, in part, by deacetylating the p53 protein at lysine 382 and inactivating p53-mediated transcription and apoptosis. Recently, SIRT1 was shown to control Bax-induced apoptosis by de-acetylating Ku70, and to inhibit Forkhead-mediated cell death (3). While SIRT1 is capable of protecting cells from p53-induced apoptosis, our work provides evidence that SIRT1 activity augments apoptosis in response to TNFá by the ability of the deacetylase to inhibit the transactivation potential of the RelA/p65 protein. Evidence suggests that histone deacetylase, SIRT1, is a mediator of life span extension by calorie restriction; however, in some cases the HDAC activity is necessary for the maintenance and survival and growth advantage in some types of cancer. SIRT1 may paradoxically increase the risk of cancer and acts as tumor promoter, it should be considered as a therapeutic target for the treatment of cancers (4). Sir1 protein has 737 amino acids, that is significantly elevated in human and mouse prostate cancer (5). SIRT1 represses Forkhead transcriptional factor (FOX3) and also acts a corepressor of androgen receptor and suggest a new molecular pathway relevant to prostate cancer growth and approaches to therapy. The Anti-SIR1-selective antibodies are generated against conserved sequence (aa 33-55 rat sequence) that is unique to SIR1 protein and is common in human, mouse, cat, bovine and several other species. The SIR1-selective antibodies are affinity purified against immobilized antigen based affinity chromatography which yielded epitope-pecific antibodies. The SIR1antibodies label a 90-92 kDa and some smaller bands (identity of these bands is not known) in PC-SIR1 Western blot positive control samples. Anti-SIR1-selective antibodies can be conjugated with secondary enzymes or coupled to fluorescent dyes for IHC, confocal or other studies at a nominal cost